Lv7
3920 积分 2022-05-23 加入
FDA/CDER/OND Experience With New Approach Methodologies (NAMs)
2天前
已完结
Rethinking the role of synergy calculations in the next century of drug combination discovery
2天前
已完结
A CDER perspective: Landscape of New Approach Methodologies (NAMs) submitted in drug development programs
2天前
已完结
Rethinking the role of synergy calculations in the next century of drug combination discovery
8天前
已完结
Pancreatic cancer
10天前
已完结
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
10天前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
10天前
已完结
Evaluating the Impact of AI-Based Model-Informed Drug Development (MIDD): A Comparative Review
13天前
已完结
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development
13天前
已完结
Model‐Informed Drug Development Approaches to Assist New Drug Development in the COVID‐19 Pandemic
13天前
已完结
皖公网安备34019202002308
